134 related articles for article (PubMed ID: 38922613)
1. Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes.
Edmonston D; Lydon E; Mulder H; Chiswell K; Lampron Z; Marsolo K; Goss A; Ayoub I; Shah RC; Chang AR; Ford DE; Jones WS; Fonesca V; Machineni S; Fort D; Butler J; Hunt KJ; Pitlosh M; Rao A; Ahmad FS; Gordon HS; Hung AM; Hwang W; Bosworth HB; Pagidipati NJ
JAMA Netw Open; 2024 Jun; 7(6):e2418808. PubMed ID: 38922613
[TBL] [Abstract][Full Text] [Related]
2. Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes.
Vart P; Vaduganathan M; Jongs N; Remuzzi G; Wheeler DC; Hou FF; McCausland F; Chertow GM; Heerspink HJL
Clin J Am Soc Nephrol; 2022 Dec; 17(12):1754-1762. PubMed ID: 36414316
[TBL] [Abstract][Full Text] [Related]
3. Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study.
Forbes AK; Hinton W; Feher MD; Elson W; Joy M; Ordóñez-Mena JM; Fan X; Cole NI; Banerjee D; Suckling RJ; de Lusignan S; Swift PA
EClinicalMedicine; 2024 Feb; 68():102426. PubMed ID: 38304744
[TBL] [Abstract][Full Text] [Related]
4. Real-World Diagnosis and Treatment of Diabetic Kidney Disease.
Rodriguez F; Lee DJ; Gad SS; Santos MP; Beetel RJ; Vasey J; Bailey RA; Patel A; Blais J; Weir MR; Dash R
Adv Ther; 2021 Aug; 38(8):4425-4441. PubMed ID: 34254257
[TBL] [Abstract][Full Text] [Related]
5. A Population-Based Analysis of Quality Indicators in CKD.
Manns L; Scott-Douglas N; Tonelli M; Weaver R; Tam-Tham H; Chong C; Hemmelgarn B
Clin J Am Soc Nephrol; 2017 May; 12(5):727-733. PubMed ID: 28377473
[TBL] [Abstract][Full Text] [Related]
6. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
Wang PT; Huang YB; Lin MY; Chuang PF; Hwang SJ
Kaohsiung J Med Sci; 2012 Sep; 28(9):477-83. PubMed ID: 22974666
[TBL] [Abstract][Full Text] [Related]
7. High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.
Fried L; Schmedt N; Folkerts K; Bowrin K; Raad H; Batech M; Kovesdy C
Nephrol Dial Transplant; 2023 Feb; 38(3):630-643. PubMed ID: 35389468
[TBL] [Abstract][Full Text] [Related]
8. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020.
Nicholas SB; Daratha KB; Alicic RZ; Jones CR; Kornowske LM; Neumiller JJ; Fatoba ST; Kong SX; Singh R; Norris KC; Tuttle KR
Diabetes Obes Metab; 2023 Oct; 25(10):2970-2979. PubMed ID: 37395334
[TBL] [Abstract][Full Text] [Related]
9. ACE inhibitor or ARB treatment among patients with diabetes and chronic kidney disease.
Fried LF; Petruski-Ivleva N; Folkerts K; Schmedt N; Velentgas P; Kovesdy CP
Am J Manag Care; 2021 Dec; 27(20 Suppl):S360-S368. PubMed ID: 34878753
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study.
Chu L; Fuller M; Jervis K; Ciaccia A; Abitbol A
Clin Ther; 2021 Sep; 43(9):1558-1573. PubMed ID: 34426012
[TBL] [Abstract][Full Text] [Related]
11. Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
Fletcher RA; Jongs N; Chertow GM; McMurray JJV; Arnott C; Jardine MJ; Mahaffey KW; Perkovic V; Rockenschaub P; Rossing P; Correa-Rotter R; Toto RD; Vaduganathan M; Wheeler DC; Heerspink HJL; Neuen BL
J Am Soc Nephrol; 2023 Dec; 34(12):1965-1975. PubMed ID: 37876229
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Sharma P; Blackburn RC; Parke CL; McCullough K; Marks A; Black C
Cochrane Database Syst Rev; 2011 Oct; (10):CD007751. PubMed ID: 21975774
[TBL] [Abstract][Full Text] [Related]
13. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
Mayyas F; Bataineh W; Jarab A
Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537
[TBL] [Abstract][Full Text] [Related]
14. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
15. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
[TBL] [Abstract][Full Text] [Related]
16. Evaluating prescription of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in patients with diabetes and albuminuria.
Chienwichai K; Chaloemwa P; Sangkaew S; Chang A
Clin Nephrol; 2024 Jun; 101(6):277-286. PubMed ID: 38606848
[TBL] [Abstract][Full Text] [Related]
17. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.
Jeong SJ; Lee SE; Shin DH; Park IB; Lee HS; Kim KA
BMC Nephrol; 2021 May; 22(1):177. PubMed ID: 33990175
[TBL] [Abstract][Full Text] [Related]
18. Quality of Chronic Kidney Disease Management in Canadian Primary Care.
Bello AK; Ronksley PE; Tangri N; Kurzawa J; Osman MA; Singer A; Grill AK; Nitsch D; Queenan JA; Wick J; Lindeman C; Soos B; Tuot DS; Shojai S; Brimble KS; Mangin D; Drummond N
JAMA Netw Open; 2019 Sep; 2(9):e1910704. PubMed ID: 31483474
[TBL] [Abstract][Full Text] [Related]
19. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Cooper TE; Teng C; Tunnicliffe DJ; Cashmore BA; Strippoli GF
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD007751. PubMed ID: 37466151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
